Modification of EBV-Associated Pathologies and Immune Control by Coinfections

The oncogenic Epstein-Barr virus (EBV) persistently infects more than 95% of the human adult population. Even so it can readily transform human B cells after infection in vitro, it only rarely causes tumors in patients. A substantial proportion of the 1% of all human cancers that are associated with EBV occurs during coinfections, including those with the malaria parasite Plasmodium falciparum, the human immunodeficiency virus (HIV), and the also oncogenic and closely EBV-related Kaposi sarcoma-associated herpesvirus (KSHV). In this review, I will discuss how these infections interact with EBV, modify its immune control, and shape its tumorigenesis. The underlying mechanisms reveal new aspects of EBV-associated pathologies and point toward treatment possibilities for their prevention by the human immune system.

Automated summary

The article discusses the impact of coinfections with EBV and other pathogens, as well as how these infections modify EBV's immune control and shape tumorigenesis.-New insights are provided into EBV-pathologies and possible treatment opportunities through prevention by the human immune system.